Stay updated with breaking news from Mark Gergen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or...
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
Poseida announced a strategic global collaboration agreement with Roche potentially worth up to $6 billion. See why I feel PSTX stock appears undervalued.
Aristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and Pfizer - read this article along with other careers information, tips and advice on BioSpace
San Francisco District Attorney Brooke Jenkins’ disclosure caused controversy because she said she worked on Chesa Boudin's recall in a volunteer capacity.